The Swedish Research Council has analyzed the development of drug trials in Sweden between 2010 and 2016 by focusing on the number of patients scheduled to participate in trials. The report shows, among other things, that participation of Swedish patients in trial and the proportion of children and adolescents is low regardless of the diagnosis area. The highest participation rate is seen among patients diagnosed with blood disorders or disorders in the immune system, where 1.5 percent participate in trials. Here you can read the full report “Statistics for drug tests from a patient perspective” (Swedish only).